Our take
Moon Surgical takes a different path from full telerobotic systems. Maestro works alongside standard laparoscopic tools at the bedside, so hospitals and surgery centers can add robotic help without a console or a new way of operating.6,3
Progress is steady: two FDA clearances, an AI camera feature called ScoPilot, software version 2.7 with automated setup, and a KARL STORZ collaboration that widens its reach. The weak points are early sales, with only a handful of named sites, and prices that are not published.2,4,5,1
Scores by criterion
Each criterion is defined on our methodology page.
Who uses Moon Surgical and what it's for
Hospitals and ambulatory surgery centers use Maestro across laparoscopic procedures. Its two arms hold cameras and instruments in place, and the surgeon positions them by hand and fits nearly any standard laparoscopic tool.6,5
Named sites include Lee Health and Surgeon's Point Surgery Center.1
History
Moon Surgical, first called MastOR, was founded in Paris in June 2020 by surgeon Brice Gayet, with Anne Osdoit as CEO, inside Sofinnova Partners' MD Start accelerator. It raised a $31.3 million Series A in May 2022 and a $55.4 million Series B led by Sofinnova Partners and NVIDIA in May 2023.2
Maestro received its first FDA clearance in December 2022 and clearance for the commercial version in June 2024. In July 2026 Moon Surgical and KARL STORZ announced a commercial collaboration, starting in the United States.2,3,5
Maestro
Maestro is a small system that fits into existing laparoscopic workflows across indications. Sofinnova says it targets the 18.8 million annual soft tissue procedures not served by telerobotic systems.3
Software version 2.7, released in June 2026, added automated setup, an improved ScoPilot camera assistant, and automated operative reports through a third-party AI app. It also cut boot time by 40%.4
Pricing
Moon Surgical does not publish prices for Maestro or its software.1
Competitive landscape
| Company | Product | Pricing model | Deployment footprint | Where Moon Surgical wins or loses |
|---|---|---|---|---|
| Moon Surgical | Maestro bedside assistant with ScoPilot AI camera control4 | Not published1 | FDA cleared in 2024; dataset of more than 3,000 procedures3,4 | Bedside robotic assistant for standard laparoscopy; prices not published |
| CMR Surgical (Versius) | Versius Plus modular surgical robot8 | Not published8 | 45,000 cases worldwide; FDA 510(k) for gallbladder removal8 | CMR wins on a full telerobotic system for complex cases. Moon wins on adding robotic help to standard laparoscopy. |
| Distalmotion (DEXTER) | DEXTER soft-tissue surgical robot with a small, mobile footprint9 | Not published9 | Almost 3,000 patients treated; three US clearances9 | Distalmotion wins on a lightweight telerobot for ambulatory sites. Moon wins on working with the surgeon at the bedside. |
| SS Innovations | SSi Mantra modular surgical robot10 | Less than a third of a da Vinci's price in a 2022 report11 | 224 systems in twelve countries by June 30, 2026; not yet FDA cleared12,13 | SS Innovations wins on a low-cost telerobot. Moon wins on fitting existing laparoscopic tools and workflows. |
| Intuitive (da Vinci) | da Vinci multi-port and single-port surgical systems14 | Sales plus leases, many with usage-based payments14 | About 12,094 systems installed at September 30, 202614 | Intuitive wins on scale and clinical evidence. Moon wins on a smaller system for the many procedures not done robotically. |
Limits
Prices are not published.1
Revenue is not disclosed. We estimate it at $5 million to $10 million, based on a commercial launch that began in 2024 and a dataset of more than 3,000 procedures. This is an estimate, not a reported figure.3,4
Maestro assists the surgeon rather than replacing laparoscopic instruments, so it does not compete for complex procedures that need a full telerobotic system.3
What customers say
Where it helps
Sofinnova says Maestro can make procedure times shorter and more predictable and allows alternative staffing models in the operating room.3
With KARL STORZ, Moon Surgical pairs Maestro with 3D visualization and instruments for hospitals and ambulatory surgery centers.5
Where it falls short
Hospitals that want a full telerobotic system for complex procedures may get more from CMR Surgical or Distalmotion.
Leadership
Anne Osdoit
CEOOsdoit is a biomedical engineer and a partner at Sofinnova Partners, where she has run the MD Start medtech accelerator since 2015.7
Sources
- Moon Surgical, Homepage, accessed November 3, 2026
- Moon Surgical, Company, accessed November 3, 2026
- Sofinnova Partners, Moon Surgical receives second FDA clearance, covering its commercial Maestro surgical robotics system, June 4, 2024, accessed November 3, 2026
- PR Newswire, Moon Surgical expands Maestro platform into a multi-model physical AI platform with software version 2.7, June 9, 2026, accessed November 3, 2026
- PR Newswire, Moon Surgical and KARL STORZ announce strategic commercial collaboration, July 22, 2026, accessed November 3, 2026
- Fierce Biotech, Moon Surgical sets up robotic assistant launch with FDA clearance, first-in-human study, December 19, 2022, accessed November 3, 2026
- Sofinnova Partners, Anne Osdoit, accessed November 3, 2026
- CMR Surgical, Home page, accessed November 1, 2026
- Distalmotion, Distalmotion raises $150 million, November 18, 2025, accessed November 1, 2026
- SS Innovations, Investor overview, accessed November 1, 2026
- Business Standard, SSI Mantra costs one-third of global price, September 15, 2022, accessed November 1, 2026
- SS Innovations, Second quarter 2026 financial results, August 13, 2026, accessed October 31, 2026
- SS Innovations, Response to FDA request for additional information on the SSi Mantra 510(k), October 13, 2026, accessed October 31, 2026
- Intuitive Surgical, Form 10-Q for the quarter ended September 30, 2026, accessed November 1, 2026
